Related Experiment Video
Updated: Aug 30, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Case of buprenorphine-associated central sleep apnea resolving with dose reduction
Vladimir Tchikrizov1, Allen C Richert2, Saurabh B Bhardwaj3
1Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Mississippi. ORCID: https://orcid.org/0000-0002-2429-7529.
Abstract:
Aside from respiratory suppression in overdose, full opioid agonist agents are known to cause sleep-disordered breathing (SDB). The increasing rates of opioid overdose in the United States have led to increasing use of medication-assisted treatments for opioid use disorders. Dose-dependent increase in SDB has been documented with methadone. There is emerging literature in the form of case reports providing evidence of buprenorphine and buprenorphine-naloxone contributing to sleep apnea. We report an additional case of a female patient developing central sleep apnea during initiation of buprenorphine-naloxone treatment. The condition resolved with dose reduction.
More Related Videos
Related Concept Videos
CNS Depressants: Barbiturates and Benzodiazepines
Sleep Apnea
The condition is more prevalent among...
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...

